Table 2.

Effect of 10 years' treatment with metformin or chlorpropamide, glibenclamide, or insulin in overweight patients with newly diagnosed type 2 diabetes

Any diabetes related end point (%)Deaths related to diabetes (%)All cause mortality (%)Myocardial infarction (%)Stroke (%)Microvascular disease (%)Median haemoglobin A1c (%)
Dietary advice plus metformin28.7 8.2*14.6 11.4*3.5 7.07.4
Dietary advice plus chlorpropamide, glibenclamide, or insulin36.810.820.014.66.37.8All similar to metformin
Dietary advice only38.913.421.717.85.69.28.0
Relative risk reduction (metformin vdietary advice)26.238.832.736.044.4 §NSSignificantly lower for all drugs compared with dietary advice
Absolute risk reduction (metformin v dietary advice)10.25.27.16.42.8 §NS
No needed to treat for 10 years to prevent one event (metformin vdietary advice)1019141636 §NS
  • * Significant versus dietary advice.

  • † Significant versus both other groups.

  • ‡ Significant versus chlorpropamide, glibenclamide, or insulin group.

  • § These results are for the differences between the metformin and the chlorpropamide, glibenclamide, or insulin group.